[1] Manne R K, Agrawal Y, Bargale A, et al. A microRNA/ubiquitin ligase feedback loop regulates slug-mediated invasion in breast cancer[J]. Neoplasia, 2017, 19(6):483-495. [2] Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors[J]. Dev Biol, 2007, 302(1):1-12. [3] Filipowicz W, Bhattacharyya S N, Sonenberg N, Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?[J].Nat Rev Genet,2008,9(2):102-114. [4] Krol J, Loedige I, Filipowicz W. The widespread regulaton of microRNA biogenesis, function and decay[J]. Nat Rev Genet, 2010, 11(9):597-610. [5] Melo S A, Esteller M. Dysregulation of microRNAs in cancer: playing with fire[J]. FEBS Lett, 2011,585(13):2087-2099. [6] Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis[J].Eur J Cancer, 2011,47(8):1127-1137. [7] Jansson M D, Lund A H. MicroRNA and cancer[J]. Mol Oncol,2012,6(6):590-610. [8] Neubauer H, Chen R, Schneck H, et al. New insight on a possible mechanism of progestogens in terms of breast cancer risk[J]. Horm Mol Biol Clin Investig, 2011, 6(1):185-192. [9] Zhang Y, Ruan X, Willibald M, et al. May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?[J]. Gynecol Endocrinol, 2016, 32(1):58-60. [10] Ruan X, Zhang Y, Mueck A O, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer[J]. Menopause, 2017, 24(2):203-209. [11] Bardou V J, Arpino G, Elledge R M, et al. Progesterone receptor status signifcantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases[J]. J Clin Oncol, 2003, 21(10):1973-1979. [12] Colozza M, Larsimont D, Piccart M J. Progesterone receptor testing: not the right time to be buried[J]. J Clin Oncol, 2005, 23(16):3867-3868. [13] Fernö M, Stål O, Baldetorp B, et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group[J]. Breast Cancer Res Treat, 2000, 59(1):69-76. [14] Kuokkanen S, Chen B, Ojalvo L, et al. Genomic profling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium[J]. Biol Reprod, 2010, 82(4):791-801. [15] Xia H F, Jin X H, Song P P, et al. Temporal and spatial regulation of let-7a in the uterus during embryo implantation in the rat[J]. J Reprod Dev, 2010, 56(1):73-78. [16] Xia H F, Jin X H, Song P P, et al. Temporal and spatial regulation of miR-320 in the uterus during embryo implantation in the rat[J]. Int J Mol Sci, 2010, 11(2):719-730. [17] Silveri L, Tilly G, Vilotte J L, et al. MicroRNA involvement in mammary gland development and breast cancer[J]. Reprod Nutr Dev, 2006, 46(5):549-556. [18] Williams K C, Renthal N E, Condon J C, et al. MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm labor[J]. Proc Natl Acad Sci U S A, 2012, 109(19):7529-7534. [19] Adams B D, Furneaux H, White B A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines[J]. Mol Endocrinol, 2007, 21(5):1132-1147. [20] Castellano L, Giamas G, Jacob J, et al. The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response[J]. Proc Natl Acad Sci USA, 2009, 106(37):15732-15737. [21] Pandey D P, Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA[J]. Mol Cell Biol, 2009, 29(13):3783-3790. [22] Zhao J J, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer[J]. J Biol Chem, 2008, 283(45):31079-31086. [23] Cohen A, Shmoish M, Levi L, et al. Alterations in micro-ribonucleic acid expression profiles reveal a novel pathway for estrogen regulation[J]. Endocrinology, 2008, 149(4):1687-1696. [24] Klinge C M. Estrogen regulation of microRNA expression[J]. Curr Genomics, 2009,10(3): 169-183. [25] Nothnick W B, Healy C, Hong X. Steroidal regulation of uterine miRNAs is associated with modulation of the miRNA biogenesis components Exportin-5 and Dicer1[J]. Endocrine, 2010, 37(2):265-273. [26] Cizeron-Clairac G, Lallemand F, Vacher S,et al, MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?[J]. BMC Cancer,2015,15:499 [27] Gilam A, Shai A, Ashkenazi I, et al. MicroRNA regulation of progesterone receptor in breast cancer[J]. Oncotarget, 2017, 8(16):25963-25976. [28] Cochrane D R, Spoelstra N S, Richer J K. The role of miRNAs in progesterone action[J]. Mol Cell Endocrinol,2012,357(1-2):50-59. [29] Nothnick W B, Healy C,Hong X. Steroidal regulation of uterine miRNAs is associated with modulation of the miRNA biogenesis components Exportin-5 and Dicer1[J]. Endocrine,2010,37(2): 265-273. [30] Yuan D Z,Yu L L,Qu T, et al.Identification and characterization of progesterone- and estrogen-regulated microRNAs in mouse endometrial epithelial cells[J]. Reprod Sci, 2015,22(2): 223-234. [31] Cochrane D R, Jacobsen B M, Connaghan K D, et al. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer[J]. Mol Cell Endocrinol, 2012, 355(1): 15-24. [32] Finlay-Schultz J, Cittelly D M,Hendricks P,et al. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a[J]. Oncogene, 2015,34(28): 3676-3687. [33] Cittelly DM, Finlay-Schultz J, Howe E N, et al. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4[J]. Oncogene, 2013, 32(20): 2555-2564. [34] Rivas M A, Venturutti L, Huang Y W,et al. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development[J]. Breast Cancer Res, 2012, 14(3):R77. [35] Maillot G, Lacroix-Triki M, Pierredon S, et al. Widespread estrogen dependent repression of micrornas involved in breast tumor cell growth[J]. Cancer Res, 2009, 69(21):8332-8340. [36] Lange C A. Challenges to defining a role for progesterone in breast cancer[J]. Steroids, 2008, 73(9-10):914-921. [37] Panda H, Chuang T D, Luo X, et al. Endometrial miR-181a and miR-98 expression is altered during transition from normal into cancerous state and target PGR, PGRMC1, CYP19A1, DDX3X, and TIMP3[J]. J Clin Endocrinol Metab, 2012, 97(7): E1316-1326. [38] Lu Z, Ye Y, Jiao D, et al. miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status[J]. Oncol Lett, 2012, 4(5): 1027-1032. [39] Cui W, Li Q, Feng L, et al. MiR-125-3p regulates progesterone receptors and involves development and lactation of mouse mammary gland[J]. Mol Cell Biochem, 2011, 355(1-2):17-25. |